Latest Medicine stories from Life.
In the latest Pharmalittle update, the U.S. is applying pressure on Germany regarding drug pricing policies, alongside notable changes within the FDA and developments in biotech clinical trials.
The DOJ has accused Yale and UCLA medical schools of potentially discriminatory admissions practices against white and Asian applicants, highlighting ongoing debates about equity in education.
In a significant development, BeOne has received FDA approval for its lymphoma treatment. Meanwhile, Regenxbio is making strides in Duchenne gene therapy, among other biotech updates.
Biogen has shared mixed findings from a mid-stage trial for an Alzheimer’s treatment aimed at the tau protein, amidst other industry news.
Preliminary government data indicates a 14% decrease in drug overdose deaths in 2025, with around 70,000 fatalities reported. However, experts express concern over potential policy and drug supply changes.
Recent findings suggest a potential connection between gene therapy viruses and a tumor in a young boy, raising important questions about the safety of such treatments.
Encoded Therapeutics has alerted gene therapy firms about potential trade-offs associated with a drug designed to enhance safety, which may inadvertently reduce effectiveness.
A boy's tumor has been linked to gene therapy viruses, prompting doctors to emphasize the need for careful consideration of the rare risks versus the significant benefits of such treatments.
The recent resignation of the FDA head has raised alarms about the agency's stability, with Kyle Diamantas stepping in as acting leader during a critical time.
In a significant shift at the Food and Drug Administration, Commissioner Marty Makary is stepping down following a challenging period in leadership, with Diamantas taking over.
As competition in the telehealth sector intensifies, Hims has reported a decline in sales. The company is navigating a challenging landscape, with significant developments in the biotech field.
STAT highlights the ongoing challenges America faces in tackling excessive alcohol consumption, revealing a historical pattern of neglect.
Pharmaceutical companies have ramped up their lobbying efforts, spending over $130 million in 2025, while Bristol-Myers Squibb has announced a new partnership with a Chinese firm.
The gene therapy community expresses concern over the lack of information from Capsida regarding the brain receptor involved in a recent fatal incident.
Researchers are investigating how generative AI could potentially decrease the reliance on animal experiments in drug development, addressing ethical concerns.
The emotional toll of losing a pet extends beyond humans, affecting surviving animals as well. This piece reflects on the grief experienced by both parties.
Recent reports indicate that significantly fewer seniors are utilizing expensive Alzheimer's medications than initially anticipated by Medicare.
Recent developments in biotech include Astellas' promising treatment for rare diseases, amid challenges in Alzheimer's drug rollout and insights from a China-based heart drug startup.
Following a challenging period marked by both remarkable recoveries and tragic losses, Astellas is revisiting its gene therapy approach for XLMTM, offering renewed hope to affected families.
In a recent discussion, Dr. Glaucomflecken highlights the necessity of maintaining local medical practices to better serve patients and communities, urging for national attention on the issue.